Heska Announces Q3 Results
November 09 2006 - 9:00AM
PR Newswire (US)
$864 thousand in Net Income Exceeds Guidance LOVELAND, Colo., Nov.
9 /PRNewswire-FirstCall/ -- Heska Corporation (NASDAQ:HSKA) today
reported financial results for its third quarter ended September
30, 2006. (Logo:
http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO) Heska
Corporation ("Heska" or the "Company") third quarter results
include: -- $15.6 million in Core Companion Animal Health segment
product revenue - the highest third quarter result in Company
history -- Gross profit of $7.9 million - the highest third quarter
result in Company history -- Gross margin improvement of 3
percentage points compared to prior year third quarter to 42.7%
"This is the first time Heska has been profitable for the January
through September nine month period. In addition, our gross margin
increased five points in this period as compared to the same period
last year," said Robert Grieve, Heska's Chairman and CEO. "For the
quarter, our total revenue and operating expense results were
consistent with our guidance and we did marginally better than
guidance on the gross margin line. Investors will recall that our
third quarter 2005 results set a high bar for the quarter we are
reporting today." Segment Product Revenue Total product revenue for
the third quarter of 2006 was $18.2 million, down 4% from $19.0
million in the third quarter of 2005. Heska Corporation's business
is comprised of two reportable segments -- Core Companion Animal
Health and Other Vaccines, Pharmaceuticals and Products. Product
revenue from these segments is as follows: Core Companion Animal
Health This segment includes revenue from the Company's diagnostic
and monitoring instruments and supplies as well as single use,
point-of-care tests, pharmaceuticals and vaccines, primarily for
canine and feline use. In the third quarter of 2006, this segment
generated product revenue of $15.6 million, up 1% as compared to
$15.5 million in the third quarter of 2005. In the third quarter of
2005, the Company sold approximately $600 thousand of used
hematology products back to its previous hematology supplier. No
such sales occurred in the third quarter of 2006. Other Vaccines,
Pharmaceuticals and Products This segment includes revenue from
private label vaccine and pharmaceutical production, primarily for
cattle but also for other animals including small mammals, horses
and fish. In the third quarter of 2006, this segment generated
product revenue of $2.6 million, down 27% as compared to $3.5
million in the third quarter of 2005. Investor Conference Call
Management will conduct a conference call on Thursday, November 9,
2006 at 9:00 a.m. MST (11:00 a.m. EST) to discuss the third quarter
2006 financial results. To participate, dial (866) 249-5225
(domestic) or (303) 205-0066 (international); the conference call
access number is 11074573. The conference call will also be
broadcast live over the Internet at http://www.heska.com/. To
listen, simply log on to the web at this address at least ten
minutes prior to the start of the call to register, download and
install any necessary audio software. Telephone replays of the
conference call will be available for playback until November 22,
2006. The telephone replay may be accessed by dialing (800)
405-2236 (domestic) or (303) 590-3000 (international). The webcast
replay may be accessed from Heska's home page at
http://www.heska.com/ until November 22, 2006. About Heska Heska
Corporation (NASDAQ:HSKA) sells advanced veterinary diagnostic and
other specialty veterinary products. Heska's state-of-the-art
offerings to its customers include diagnostic and monitoring
instruments and supplies as well as single use, point-of-care
tests, pharmaceuticals and vaccines. The company's core focus is on
the canine and feline markets where it strives to provide high
value products for unmet needs in veterinary medicine. For further
information on Heska and its products, visit the company's website
at http://www.heska.com/. Forward-Looking Statements This
announcement contains forward-looking statements regarding Heska's
future financial and operating results. These statements are based
on current expectations and are subject to a number of risks and
uncertainties. In addition, factors that could affect the business
and financial results of Heska generally include the following:
uncertainties regarding Heska's ability to achieve sustained and/or
material profitability; uncertainties regarding the accuracy of any
current or future financial guidance; risks regarding Heska's
ability to successfully market, sell and distribute its products;
uncertainties regarding Heska's reliance on third parties who Heska
has granted substantial marketing rights to certain of Heska's
existing products; competition; uncertainties regarding the outcome
of relationships, collaborations and agreements with third parties
from which Heska is hoping to generate new product opportunities or
other benefits; risks regarding Heska's reliance on third-party
suppliers, which is substantial; risks regarding the
commercialization and market acceptance of products Heska may
introduce in the future; uncertainties regarding the impact of
revenue fluctuations or shortfalls versus our expectations on
Heska's cash flow and liquidity as many of Heska's expenses are
fixed; uncertainties regarding the cost and outcome of litigation
Heska may be involved in; and the risks set forth in Heska's
filings and future filings with the Securities and Exchange
Commission, including those set forth in Heska's Annual Report on
Form 10-K for the year ended December 31, 2005 and Quarterly Report
on Form 10-Q for the quarter ended June 30, 2006. Financial Table
Follows: HESKA CORPORATION AND SUBSIDIARIES Condensed Consolidated
Statements of Operations (in thousands, except per share amounts)
(unaudited) Three Months Ended Nine Months Ended September 30,
September 30, 2005 2006 2005 2006 Revenue, net: Product revenue,
net: Core companion animal health $15,487 $15,612 $41,667 $44,523
Other vaccines, pharmaceuticals and products 3,497 2,561 10,324
8,790 Total product revenue, net 18,984 18,173 51,991 53,313
Research, development and other 356 432 1,068 1,329 Total revenue
19,340 18,605 53,059 54,642 Cost of revenue: Cost of products sold
11,358 10,348 33,167 31,355 Cost of research, development and other
304 321 771 869 Total cost of revenue 11,662 10,669 33,938 32,224
Gross profit 7,678 7,936 19,121 22,418 Operating expenses: Selling
and marketing 3,484 3,490 10,711 10,771 Research and development
884 814 3,061 2,663 General and administrative 1,838 2,482 5,687
7,170 Total operating expenses 6,206 6,786 19,459 20,604 Income
(loss) from operations 1,472 1,150 (338) 1,814 Interest and other
expense, net 238 263 503 809 Income (loss) before income taxes
1,234 887 (841) 1,005 Income tax expense -- 23 -- 78 Net income
(loss) $1,234 $864 $(841) $927 Basic and diluted net income (loss)
per share $0.02 $0.02 $(0.02) $0.02 Weighted average shares used to
compute basic net income (loss) per share 49,817 50,411 49,573
50,264 Weighted average shares used to compute diluted net income
(loss) per share 50,133 52,940 49,573 52,442 Balance Sheet Data (in
thousands) (unaudited) December 31, September 30, 2005 2006 Cash
and cash equivalents $5,231 $5,259 Total current assets 26,845
30,460 Total assets 36,784 38,271 Line of credit 9,453 8,834
Current portion of long-term debt and capital leases 1,263 1,275
Total current liabilities 20,722 23,156 Long-term debt and capital
leases 2,703 2,122 Stockholders' equity 3,233 4,923
http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO
http://photoarchive.ap.org/ DATASOURCE: Heska Corporation CONTACT:
Jason Napolitano, Executive Vice President & CFO of Heska
Corporation, +1-970-493-7272, ext. 4105 Web site:
http://www.heska.com/
Copyright
Heska (NASDAQ:HSKA)
Historical Stock Chart
From May 2024 to Jun 2024
Heska (NASDAQ:HSKA)
Historical Stock Chart
From Jun 2023 to Jun 2024